Deciphering and reversing tumor immune suppression.

By Greg T. Motz, George Coukos. Immunity, 2013

606 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6f9911ff81b3185c2a1178fc05c0cbabaf8a85e0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Daniel S. Chen
2. Rakesh K. Jain
3. N. Ferrara
4. G. Bergers
5. I. Mellman
6. D. Hanahan

In Oncology

1. D. Hanahan
2. Rakesh K. Jain
3. N. Ferrara
4. Daniel Chen
5. R. Apte
6. G. Bergers
7. Daniel S. Chen
8. I. Mellman

Citations in the corpus

• Functional morphology of the blood-brain barrier in health and disease (2018, neutral): “The tumour pro-angiogenic vasculature thereby prevents the recruitment of tumour-reactive T lymphocytes and fosters an immunosuppressive microenvironment that allows gliomas to evade host immune-surveillance [84].”
• VEGF in Signaling and Disease: Beyond Discovery and Development (2019, result): “This is consistent with the observed role of VEGF in downmodulating immunity (Motz and Coukos, 2013; Ohm and Carbone, 2001).”
• Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation (2017, background): “Tumor angiogenic vasculature thwarts the extravasation of tumor-reactive T cells and fosters an immunosuppressive microenvironment that allows tumors to evade host immunosurveillance (8).”
• Current Challenges in Cancer Treatment. (2016, background): “Incomplete tumor elimination is followed by an equilibrium phase, in which cancer cells shape their microenvironment and initiate complex mechanisms of immune evasion that will finally lead to immune escape and tumor progression.(21,25) Actually, immune evasion is considered one of the core hallmark”
• Oncology meets immunology: the cancer-immunity cycle. (2013, result): “Despite these findings, recent results from human cancer have demonstrated that overcoming negative regulators to T cell responses in lymphoid organs (checkpoints) and in the tumor bed (immunostat function) are likely to explain the failure of immune protection in many patients (Mullard, 2013).”
• ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, positive): “…and immunosuppressive phenotype (Casazza et al., 2014; Colegio et al., 2014; Finger and Giaccia, 2010; Hanahan and Coussens, 2012; Keith et al., 2012; Motz and Coukos, 2013; Noy and Pollard, 2014; Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 605 NS, not significant; NA, not available. aNo…”